Charles Schwab Investment Management Inc. Grows Stake in Zura Bio Limited (NASDAQ:ZURA)

Charles Schwab Investment Management Inc. grew its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 51.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 291,807 shares of the company’s stock after purchasing an additional 98,972 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Zura Bio were worth $1,185,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ZURA. Point72 Asset Management L.P. acquired a new position in Zura Bio during the 2nd quarter valued at about $8,446,000. Great Point Partners LLC increased its holdings in shares of Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. Armistice Capital LLC raised its position in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Palumbo Wealth Management LLC acquired a new stake in Zura Bio in the 3rd quarter worth approximately $156,000. Finally, SG Americas Securities LLC acquired a new stake in Zura Bio in the 3rd quarter worth approximately $62,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Insider Activity at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of research analyst reports. Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Chardan Capital decreased their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Monday, November 18th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Price Performance

Shares of NASDAQ:ZURA opened at $2.51 on Wednesday. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $6.35. The business has a 50 day moving average of $3.69 and a two-hundred day moving average of $3.74.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). As a group, equities analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.